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Introduction: Bone metastasis remains incurable with treatment restricted to palliative care. Cabozantinib (CBZ) is
targeted against multiple receptor tyrosine kinases involved in tumour pathobiology, including hepatocyte growth
factor receptor (MET) and vascular endothelial growth factor receptor 2 (VEGFR-2). CBZ has demonstrated clinical
activity in advanced prostate cancer with resolution of lesions visible on bone scans, implicating a potential role of
the bonemicroenvironment as a mediator of CBZ effects. We characterised the effects of short-term administration
of CBZ on bone in a range of in vivomodels to determine how CBZ affects bone in the absence of tumour.
Methods: Studieswere performed in a variety of in vivomodels includingmale and female BALB/c nudemice (age 6–
17-weeks). Animals received CBZ (30mg/kg, 5×weekly) or sterile H2O control for 5 or 10 days. Effects on bone in-
tegrity (μCT), bone cell activity (PINP, TRAP ELISA), osteoblast and osteoclast number/mm trabecular bone surface,
area of epiphyseal growth plate cartilage, megakaryocyte numbers and bone marrow composition were assessed.
Effects of longer-term treatment (15-day & 6-week administration) were assessed in male NOD/SCID and beige
SCID mice.
Results: CBZ treatment had signiﬁcant effects on the bone microenvironment, including reduced osteoclast and in-
creased osteoblast numbers compared to control. Trabecular bone structure was altered after 8 administrations. A
signiﬁcant elongationof the epiphyseal growthplate, in particular thehypertrophic chondrocyte zone,was observed
in all CBZ treated animals irrespective of administration schedule. Both male and female BALB/c nude mice had in-
creased megakaryocyte numbers/mm2 tissue after 10-day CBZ treatment, in addition to vascular ectasia, reduced
bone marrow cellularity and extravasation of red blood cells into the extra-vascular bone marrow. All CBZ-
induced effects were transient and rapidly lost following cessation of treatment.
Conclusion: Short-termadministration of CBZ induces rapid, reversible effects on the bonemicroenvironment in vivo
highlighting a potential role in mediating treatment responses.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).rescent protein expressing cells
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Effective suppression of bone metastasis requires therapeutic
targeting of both the tumour and the bone microenvironment, hence
use of agents with multiple targets may provide an opportunity to im-
prove outcome for patients with skeletal metastases. Cabozantinib
(CBZ) is a receptor tyrosine kinase (RTK) inhibitor with potent activity
against multiple RTKs, including VEGFR-2 and MET, that mediate tu-
mour survival, metastasis and angiogenesis and are also expressed by
a number of cell types in bone [1–4]. This proﬁle suggests that CBZ has
potential as an anti-tumour agent for use in patients with bone
metastasis.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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demonstrated a decrease in tumour volume, tumour necrosis, suppres-
sion of tumour growth in addition to altered bone remodelling follow-
ing long-term CBZ treatment, suggesting tumour cells as well as cells
of the bone microenvironment as potential cellular targets of CBZ [5,
6]. A phase II randomized discontinuation trial in patients with ad-
vanced prostate cancer demonstrated clinical activity, including in-
creased resolution in bone scans in addition to pain relief in more
than 60% of evaluable patients [7–9]. Both clinical and preclinical studies
therefore suggest the bonemicroenvironment as a potentialmediator of
observed treatment responses. However, it is still unclear whether CBZ
targets bone metastases directly, indirectly through modulating the
bone, or both.
Bone metastasis involves complex crosstalk between the tumour
cells and cells of the bone microenvironment including osteoclasts, os-
teoblasts, haematopoietic and vascular cells. Bone turnover is regulated
through receptor activator of nuclear factor-kappa-B (RANK) and RANK
ligand (RANKL) interactions. Osteoclast differentiation and maturation
is mediated by binding of RANKL (expressed by osteoblasts) to RANK
(expressed by osteoclasts) [10]. In addition to RANK/RANKL signalling,
the MET and VEGF signalling pathways regulate the tightly balanced
coupling between osteoblasts and osteoclasts, as both cell types express
target receptors [2–4,11] and are therefore potentially affected by CBZ.
CBZ is a multiple tyrosine kinase inhibitor, also targeting Ret, Kit, Flt-
1/3/4, Tie2, and AXL, all of whichmight be involved in bone remodelling
as well as bone cell biology [12,13]. In this study we have focussed on
exploring the potential role of MET and VEGFR in the bone effects of
CBZ.
The role of VEGF in promoting tumour angiogenesis and promoting
tumour cell survival are well established, but VEGF/VEGFR signalling
also plays a pivotal role in ossiﬁcation (reviewed in [14]) and in main-
taining the balance between bone formation and resorption by regulat-
ing osteoblast and osteoclast survival and activity [15]. Crosstalk
between osteoblasts and haematopoietic stem cell niches are suggested
(reviewed in [16]); however, how communication between vascular
endothelial cells and bone cells is mediated remains to be established.
CBZ could therefore inhibit the VEGF-driven processes of vascular re-
modelling and bone turnover, both associated with tumour growth
and progression in bone.
Hepatocyte growth factor (HGF) is the only known ligand for the
RTK MET. MET/HGF signalling is instrumental in embryogenesis, cell
proliferation, motility and survival in addition to angiogenesis and
wound healing [17–20]. High levels of MET in cancer are associated
with poor prognosis and are known to promote tumour invasion, me-
tastasis, growth and survival [21]. In addition to expressingMET, osteo-
blasts and osteoclasts also secrete HGF indicating that the HGF/MET
signalling axis regulates growth, activity and survival of these cells
through both, autocrine and paracrine mechanisms [2,22,23]. In addi-
tion HGF is secreted by cells of mesenchymal origin [24] including
bone marrow stromal cells [25]. A number of cell types that play a role
in bone turnover, as well as in metastasis express target receptors of
CBZ. This includes haematopoietic cells like megakaryocytes, which in
turn are demonstrated to modify both osteoblasts and osteoclasts
in vitro [26,27].When co-culturedwithmegakaryocytes, increased oste-
oblast proliferation and decreased osteoclast formation as well as activ-
ity has been observed [26,28]. Cartilage-synthesizing chondrocytes
express receptors forMET andVEGF and are therefore also potential tar-
gets of CBZ [4,29–31]. In addition, HGF induces proliferation andmigra-
tion of endothelial cells in vitro as well as angiogenesis in vivo [19].
Taken together, these published reports support that CBZ has the capac-
ity to modify a number of cell types in the bonemicroenvironment that
contribute to both normal bone homeostasis and cancer-induced bone
disease via the targeting of MET.
The involvement of MET and VEGFR signalling in bone remodelling
and metastasis offers the opportunity for therapeutic targeting of the
bone microenvironment in addition to the cancer itself. To date, moststudies of CBZ have focused on advanced cancer-induced bone disease
[5,32,33], but the extensive loss of bone, combined with the profound
effects of increasing tumour burden in this setting, masks the effects
of therapies on the bonemicroenvironment. Indeed, initial observations
on non-tumour bearing bone inmice [32,33] indicate that CBZmayhave
direct effects on the bone microenvironment. It is therefore important
to fully elucidate the effects of CBZ on bone in the absence of tumour.
We have determined the short-term treatment effects of CBZ on the
tumour-free bone microenvironment in vivo using a range of models,
including contralateral non-tumour bearing tibiae from mice with
established prostate cancer-induced bone metastasis following long-
term treatment with CBZ. To our knowledge this is the ﬁrst comprehen-
sive study to demonstrate that treatment effects observed in models of
bone metastasis might be partially mediated by cells of the bone
microenvironment.
2. Methods
2.1. In vivo experiments
All in vivo experiments were performed in compliance with the UK
Animals (Scientiﬁc Procedures) Act 1986 and were reviewed and ap-
proved by the local Research Ethics Committee of theUniversity of Shef-
ﬁeld (Shefﬁeld, UK). Work was performed under UK Home Ofﬁce
regulations (project license 40/3531, personal license 40/10913).
2.2. Animal models
To allow comparison of the effects of CBZ in different bonemicroen-
vironments, studies were performed in animal models of different
strain, sex and age as follows: 1) 6-week old male BALB/c nude mice,
2) 6-week old female BALB/c nude mice (both Charles River, UK),
3) 8–9-week old female genetically engineered mice expressing GFP-
positive cells of the osteoblastic lineage on a BALB/c nude background
((BALB/cAnNCrl.Cg-Tg(Col1a1-GFP)Row Foxn1nu/nu, described in [34],
heterozygous, referred to as GFP Ob+mice) and 4) 17-week old female
GFP Ob+ mice (both Leeds Institute for Molecular Medicine, UK).
In murinemodels, bone remodelling is reduced with increasing age.
We therefore established effects of CBZ in young (8–9 week old) mice
with high bone turnover in addition to older (17-week old) mice with
lower bone turnover.
2.3. Drug treatment and sample collection
Cabozantinib (XL184), a kind gift from Exelixis Inc., South San
Francisco, California, USA, was prepared in sterile ﬁltered H2O. To aid
dissolution of the drug 5 μL 1 N HCl per 3 mg/mL CBZ were added ac-
cording to company recommendations and administered by oral ga-
vage. The drug suspension was prepared fresh on the day of
administration. To analyse effects of CBZ on the bone microenviron-
ment, animals were randomized in two groups receiving either 30
mg/kg CBZ (200 μL) or sterile H2O control (200 μL) 5× weekly.
To determine short-term effects of CBZ, 8–9- (high bone turnover,
n = 4/group) and 17-week old GFP Ob+ mice (low bone turnover,
n = 4/group) received 30 mg/kg CBZ or sterile H2O control 5× weekly
for 5 days (cumulative dose of 150 mg/kg). Animals were killed 24 h
after the last treatment (Fig. 1A).
6-week old male and female BALB/c nude (n = 4–5/group) as well
as female 9-week old GFP Ob+ mice (n = 4/group) were administered
30 mg/kg CBZ or sterile H2O control 5× weekly for 10 days (8 adminis-
trations in total, cumulative dose of 240mg/kg CBZ). Tomonitor the rate
of bone formation Calcein (30 mg/kg, 100 μL, i.p., Sigma-Aldrich) was
injected 6 and 2 days pre cull. Additional animals were killed on day
15 and 22 to assess the reversibility of effects 5 and 12 days after the
last administration of CBZ, respectively (Fig. 1B).
Fig. 1. Schematic outline of the in vivo studies. (A) 8–9- and 17-week old female GFP Ob+ mice (n = 4/group) received 30 mg/kg Cabozantinib (CBZ) or sterile H2O control (CTRL) 5×
weekly for 5 days via oral gavage. Animals were killed 24 h after the last treatment administration. (B) Male and female 6-week old BALB/c nude as well as 9-week old female GFP
Ob+ mice (n = 4–5/group) received 8 doses of 30 mg/kg CBZ or sterile H2O control (CTRL). Animals were killed 6 h after the last administration. To monitor if treatment effects of CBZ
were maintained once treatment was terminated additional female BALB/c nude mice were culled 5 (day 15) and 12 days (day 22) after treatment termination.
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Immediately following cull, hind legs were collected, ﬁxed in 4% PFA
for 72 h. μCT analysis was performed within 72 h, followed by decalciﬁ-
cation in 0.5M EDTA, 0.5% PFA, PBS, pH 8.Whole bloodwas collected by
cardiac puncture and spun down at 4000 rpm for 10 min at 4 °C and
serum stored at−80 °C prior to analysis of bone turnover markers.
2.5. Effects of longer-term Cabozantinib treatment
Contralateral, non-tumour bearing tibiae from castrated adult male
NOD/SCID mice (injected intratibially with VCaP BM1/cr-luc prostate
cancer cells, 30 mg/kg CBZ daily for 15 days, n = 6–7/group) [5], as
well as tibiae from 6-week old castrated male beige SCIDmice (injected
intratibially with C4-2B prostate cancer cells, 60 mg/kg CBZ 5× weekly
for 6-weeks, n = 9–10/group) [32] were analysed to determine long-
term treatment effects of CBZ on growth plate cartilage.
2.6. Micro computed tomography imaging and analysis of bone integrity
Analysis of bone volume and structure was performed by micro
computed tomography imaging of proximal tibiae using a SkyScan
1172 X-ray computed tomography (SkyScan) as reported previously
[35]. Trabecular bone volume (BV/TV in %, the percentage of the vol-
ume of interest occupied by binarised solid objects), number (Tb.N. in
mm−1) and thickness (Tb.Th. in mm) were determined.
2.7. Histological analysis
All histological analysis was performed on 2 non-serial parafﬁn em-
bedded histological sections (3 μm) using OsteoMeasure software
(Osteometrics) and a Leica RMRB upright microscope.
2.7.1. Staining of growth plate cartilage and epiphyseal growth plate analysis
The cationic dyes Safranin-O and toluidine blue were used to visual-
ize acidic proteoglycan in growth plate cartilage of tibiae. Staining was
performed according to standard operating procedures.
Area of resting/proliferating and hypertrophic chondrocyte zone
were determined using OsteoMeasure software and normalised tototal epiphyseal growth plate area by interactively drawing around
the corresponding chondrocyte stacks (Fig. 4A).2.7.2. Bone cell quantiﬁcation
Tartrate-resistant acid phosphatase (TRAP) staining was used to
quantify the number of osteoclasts on histological sections of tibiae
and osteoblasts were quantiﬁed on H&E stained histological sections —
staining was performed in line with previously published studies [34,
35]. Osteoclasts were identiﬁed by their bright pink appearance after
TRAP staining, multiple nuclei and their rufﬂed boarder (Fig. 2A). Oste-
oblasts were identiﬁed by their characteristic cuboidal morphology
(Fig. 2A) and all trabecular bone surfaces 125 μmaway from the growth
plate were scored to determine bone cell number/mm trabecular bone
excluding all cortical bone surfaces.
Megakaryocytes (identiﬁed by their characteristic shape and large
lobulated nucleus) number/mm2 bone surface was counted manually
on H&E-stained histological sections (conﬁrmed by histopathologist
K.H.). Quantiﬁcation commenced 125 μm from the growth plate and
an area 1250 μm in length was scored (Fig. 5A).2.8. Visualisation of vascular endothelial cells by immunoﬂuorescence
To visualize effects of CBZ on the bonemarrow vasculature, immuno-
ﬂuorescence staining against the endothelial cell marker endomucin was
performed. Antigen retrieval was performed using Tris-buffer (15 min,
95 °C), unspeciﬁc binding blocked by incubation in 5% normal goat
serum/3% BSA and primary antibody (Endomucin V.7C7, rat monoclonal,
Santa Cruz, sc-65495) incubated at 4 °C over night. This was followed by
incubation in secondary antibody (Alexa ﬂuor 555, goat anti-rat Igg,
LifeTechnologies, A21434, 1 h) and images acquired using a Leica
DMI4000B microscope and LAS AF Lite software (20× objective) and a
Nikon A1 confocal microscope with NIS Elements software (40×
objective).2.9. Bone turnover markers
Rat/Mouse PINP Enzyme immunoassay for N-terminal propeptide
and MouseTRAP™ Assay were performed to determine osteoblast and
Fig. 2. Effects of 5-day treatment with Cabozantinib on bone. (A) Representative TRAP-stained histological bone tissue sections from 8–9 week old mice illustrating the increase in oste-
oblast and decrease in osteoclast numbers following CBZ treatment vs. CTRL. Representative osteoclasts are highlighted with black asterisk, osteoblasts with black arrowhead, 40× objec-
tive, scale bar is 50 μm, BM= Bonemarrow, Tb= Trabecular bone. (B) GFP+ osteoblastic cells lining trabecular bone surfaces by immunoﬂuorescence, 20× objective. GFP+ osteoblasts
are shown in green. (C&F) Osteoblast number and (D&G) osteoclast number/mm trabecular bone surface were scored on H&E- and TRAP-stained tissue sections, respectively after 5-day
administration of Cabozantinib (CBZ, 30mg/kg) orH2O control (CTRL). (H&H) Trabecular bone volume (%) of the proximal tibiae determined using μCTanalysis. (C–E) represent results for
17-week old (n=4/group) and (F–H) for 8–9-week old GFPOb+mice (n=4/group). Student's t-test: ns is non-signiﬁcant,* is p ≤ 0.05, ** is p ≤ 0.01, *** is p ≤ 0.001. All data showmean±
SEM.
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manufacturer's instructions (both Immunodiagnostic Systems, UK).
2.10. Statistical analysis
All statistical analysis was performed using Prism GraphPad (Ver-
sion 6.0). The applied statistical analysis is indicated in each ﬁgure leg-
end. Analysis was performed using Student's t-test or two-way
ANOVAwith Bonferroni post-test. p-Values of p ≤ 0.05were considered
signiﬁcant.
3. Results
3.1. The bone microenvironment is modiﬁed following 5-days of
Cabozantinib administration
In this study we aimed to establish whether short-term treatment
with CBZ affects the bonemicroenvironment. We therefore initially ad-
ministered 30 mg/kg/day CBZ for 5 days (cumulative dose = 150
mg/kg) and assessed osteoblast and osteoclast number per mm trabec-
ular bone surface, aswell as bone volume and structure compared to sa-
line control. We used two cohorts of mice; 8–9-week old animalswith a
high bone turnover and 17-week old animals with a more mature skel-
eton, allowing us to compare the effects of CBZ in these different bone
microenvironments (Fig. 1).3.1.1. CBZ effects on osteoblasts
Osteoblasts were identiﬁed based on their characteristic morpholo-
gy and quantiﬁed on H&E-stained tissue sections (Fig. 2A). In addition,
we used genetically engineeredmice expressing GFP in cells of the oste-
oblastic lineage to conﬁrm the effects of CBZ on osteoblasts by immuno-
ﬂuorescence (hereafter called GFP Ob+, Fig. 2B). After 5 daily
administrations of 30 mg/kg CBZ, there was signiﬁcantly increased
numbers of osteoblasts lining the trabecular bone surfaces in 17-week
old GFP Ob+ mice (CTRL: 17.92 ± 2.11 vs. CBZ: 44.02 ± 3.63, p ≤
0.001, Fig. 2C). This effect, was also seen in 8–9-week old GFP Ob+
mice, although less prominent (CTRL: 20.60 ± 2.46 vs. CBZ: 31.96 ±
2.21, p ≤ 0.05, Fig. 2A,B&F). Despite the increase in osteoblast number,
there was no signiﬁcant difference in osteoblast activity (serum PINP
levels) between the treatment groups (17-week old GFP Ob+: CTRL:
33.63 ± 2.69 ng/mL vs. CBZ: 40.05 ± 3.48 ng/mL, 8–9-week old GFP
Ob+: CTRL: 77.86 ± 5.69 ng/mL vs. CBZ: 84.15 ± 10.64 ng/mL; Supple-
mentary Fig. 1 A&C).3.1.2. Effects on osteoclasts
The number of osteoclast/mm trabecular bone surface was deter-
mined on TRAP-stained histological sections. Five daily administrations
of CBZ induced a substantial reduction in osteoclast number/mm tra-
becular bone surfaces in 8–9-week old GFP Ob+ mice compared to
CTRL (CTRL: 6.91 ± 0.39 vs. CBZ: 3.95 ± 0.24, p ≤ 0.001, Fig. 2A&G). In
contrast, osteoclast number was not altered in older (17-week old)
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bly reﬂecting the age-related reduction in bone remodelling. Osteoclast
activity (TRAP) was not affected by CBZ administration in either model
(8–9-week old GFP Ob+: CTRL: 8.33± 0.69U/L vs. CBZ: 10.12± 1.11 U/
L; 17-week old GFP Ob+: CTRL: 11.36 ± 1.63 U/L vs. CBZ: 15.25 ±
1.47 U/L, Supplementary Fig. S1B&D).
3.1.3. Effects on trabecular bone volume and structure
To determine if the effects on osteoblasts and osteoclasts resulted in
alterations of bone structure and volume, we performed μCT analysis of
proximal tibiae after administration of 30mg/kg CBZ or CTRL for 5-days.
There was signiﬁcantly increased trabecular bone volume in 17-week
old GFP Ob+mice (p ≤ 0.01, Fig. 2E, Table 1), whereas all other analysed
bone parameters, including trabecular thickness and number remained
unaffected. No CBZ-induced alterations in bone structure were deter-
mined in 8–9-week old animals (Fig. 2H, Table 1).
Taken together, these data demonstrate that a 5-day course of CBZ
treatment is sufﬁcient to inducemodiﬁcations of osteoblasts and osteo-
clasts, although longer-term administration of CBZmight be required to
cause signiﬁcant alterations to bone structure.
3.2. A 10-day course of Cabozantinib alters bone structure andmodiﬁes key
bone cells
As the 5-day administration of 30 mg/kg CBZ (cumulative dose: 150
mg/kg) was found to rapidly modify osteoblast and osteoclast number,
with onlymodest effects on bone volume, we next increased the dosing
regimen to a total of 8 administrations of CBZ over 10 days (cumulative
dose: 240 mg/kg) (Fig. 1B).
3.2.1. Effects on osteoblasts
We found that 8 doses of CBZ resulted in signiﬁcantly increased os-
teoblast number/mm trabecular bone surface in 6-week old male
BALB/c nude mice, compared to control (CTRL: 10.54 ± 1.23 vs. CBZ:
15.01 ± 1.12, p ≤ 0.05, Fig. 3A). However, there was no effect on osteo-
blast number in the other experimental animal models receiving this
treatment regimen (6-week old female BALB/c nude: CTRL: 16.01 ±
1.48 vs. CBZ: 17.12 ± 0.97, Fig. 3C; 9-week old GFP Ob+: CTRL:
9.53 ± 0.66 vs. CBZ: 8.64 ± 1.33, Fig. 3E). Similar to 5 doses of CBZ, ad-
ministration of 8 doses did not alter serum PINP levels in these animal
models (Supplementary Fig. S1E–G). In addition, no change inTable 1
Analysis of bone structure and volume. Trabecular bone volume (BV/TV in %), number (inmm−
mg/kg Cabozantinib (CBZ) or control (CTRL) using μCTanalysis. Students t-test or (1)two-wayAN
0.05, ** is p ≤ 0.001.
BV/TV = trabecular bone volume, Tb.N. = trabecular number, Tb.Th. = trabecular thickness.
Analysis of treatment effects on
BV/TV (%)
CTRL CBZ p
5-day treatment schedule
GFP Ob+ mice
8–9-week old
12.97 ± 0.36 13.04 ± 1.60 ns 2.86
GFP Ob+ mice
17-week old
14.53 ± 0.22 16.42 ± 0.35 ** 2.57
10-day treatment schedule
Male BALB/c nude
6-week old
12.16 ± 0.84 16.01 ± 1.53 ns 3.39
Female BALB/c nude 6-week old 11.61 ± 1.31 12.18 ± 1.47 ns (1) 3.21
Female GFP Ob+ mice
9-week old
13.48 ± 0.54 18.75 ± 1.09 ** 2.65
Follow-up treatment (6-week old female BALB/c nude)
5 days post-treatment termination 11.07 ± 1.29 9.86 ± 0.95 ns (1) 2.86
12 days post-treatment termination 10.49 ± 0.85 11.64 ± 1.49 ns (1) 2.65osteoblast number or activity between the treatment groups was de-
tected at day 5 and 12 after treatment termination (Day 15 and 22, re-
spectively, data not shown).
3.2.2. Effects on osteoclasts
When compared to control, 8 doses of CBZ did not alter osteoclast
number of 6-week old male BALB/c nude mice (CTRL: 5.63 ± 0.16 vs.
CBZ: 6.56 ± 0.59, Fig. 3B) but resulted in signiﬁcantly increased osteo-
clast size (CTRL: 7.10 × 10−5 ± 4.74 × 10−6 mm2 vs. CBZ:
9.72 × 10−5 ± 6.53 × 10−6 mm2, p ≤ 0.05 — data not shown), which
may indicate a loss of activity. In contrast, there was a signiﬁcant de-
crease in osteoclast number both in 6-week old female BALB/c nude
(CTRL: 8.29 ± 0.39 vs. CBZ: 6.78 ± 0.48, p ≤ 0.05, Fig. 3D&G) and 9-
week old GFP Ob+ (CTRL: 5.99 ± 0.46 vs. CBZ: 4.15 ± 0.30, p ≤ 0.05,
Fig. 3F) treated with CBZ. Osteoclast activity was not signiﬁcantly al-
tered in 6-week old female BALB/c nude mice (CTRL: 16.21 ± 0.71 U/L
vs. CBZ: 14.11 ± 2.88 U/L, Supplementary Fig. 1I) and 9-week old GFP
Ob+mice (CTRL: 12.04± 1.19 vs. CBZ: 13.35± 1.22 U/L, Supplementa-
ry Fig. S1J). However, therewas a trend towards increased osteoclast ac-
tivity in 6-week old male BALB/c nude mice receiving CBZ (CTRL:
14.37 ± 1.05 vs. CBZ: 18.85 ± 1.87, p = 0.0817, Supplementary
Fig. S1H).
Although the CBZ induced effects on osteoclast numberwere rapidly
reversed after treatment termination (Day 10: CTRL: 8.29 ± 0.39 vs.
CBZ: 6.78 ± 0.48, p ≤ 0.05; Day 15: 7.55 ± 0.45 vs. CBZ: 7.80 ± 0.23;
Day 22: CTRL: 9.84 ± 0.35 vs. CBZ: 9.99 ± 0.60) osteoclast activity
remained signiﬁcantly elevated compared to control 12 days after ad-
ministration of the last dose of CBZ (CTRL: 9.99 ± 0.82 U/L vs. CBZ:
16.79 ± 2.85 U/L, p ≤ 0.05, Supplementary Fig. S2C).
3.2.3. Effects on trabecular bone volume and structure
We next assessed if 8 doses of CBZ (cumulative dose: 240 mg/kg)
caused alterations in trabecular bone volume, number and/or thickness
of proximal tibiae. CBZ caused signiﬁcantly increased trabecular thick-
ness in all the animalmodels (p ≤ 0.01, Table 1) when compared to con-
trol. 9-week old GFP Ob+ mice treated with CBZ additionally had
increased trabecular number (p ≤ 0.05, Table 1) and volume (p ≤ 0.01,
Table 1). These parameters were not signiﬁcantly affected in BALB/c
nude mice (Table 1) although there was a trend towards increased tra-
becular bone volume in 6-week oldmale BALB/c nudemice (p=0.0694
vs. CTRL, Table 1). The CBZ-induced increase in trabecular thicknesswas1) and thickness (inmm) of proximal tibiaewere analysed after 5 and 8 dose regimen of 30
OVAwith Bonferroni post-testwasused for statistical analysis. ns is non-signiﬁcant, * is p ≤
bone volume and structure
Tb.N. (mm−1) Tb.Th. (mm)
CTRL CBZ p CTRL CBZ p
± 0.05 2.77 ± 0.36 ns 0.045 ± 0.001 0.047 ± 0.001 ns
± 0.09 2.72 ± 0.05 ns 0.057 ± 0.002 0.060 ± 0.002 ns
± 0.24 3.84 ± 0.30 ns 0.036 ± 0.001 0.042 ± 0.001 **
± 0.31 2.817 ± 0.303 ns (1) 0.036 ± 0.001 0.043 ± 0.001 ** (1)
± 0.13 3.294 ± 0.146 * 0.051 ± 0.001 0.057 ± 0.001 **
± 0.33 2.41 ± 0.18 ns (1) 0.039 ± 0.001 0.041 ± 0.001 ns (1)
± 0.19 2.83 ± 0.30 ns (1) 0.039 ± 0.001 0.041 ± 0.002 ns (1)
Fig. 3. Effects of Cabozantinib on osteoclasts and osteoblasts. (A) Osteoblast number and (B) osteoclast number/mm trabecular bone surface were determined on H&E- and TRAP-stained
histological sections after 8 doses of 30mg/kg CBZ or sterile H2O control (CTRL) in 6-week oldmale BALB/c nudemice (n= 4/group). 6-week old female BALB/c nude (n= 5/group) and
9-week old female GFP Ob+mice (n= 4/group) received the same treatment schedule prior to analysis of (C&E) osteoblast and (D&F) osteoclast number/mm trabecular bone surface.
Representative TRAP stained histological sections of 6-week old female BALB/c nude mice are shown in (G). Black asterisk highlights osteoclasts, black arrowheads indicate osteoblasts,
40× objective, scale bar is 50 μm. Student's t-test: ns is non-signiﬁcant, * is p ≤ 0.05. All data show mean ± SEM.
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treatment (Day 15) (Table 1).
These data support that bone effects depend on continuous adminis-
tration of CBZ and vary according to age (and therefore bone turnover)
and sex of the experimental animal, as well as the parameter measured.
3.3. Effects of Cabozantinib on the epiphyseal growth plate
The epiphyseal growth plate is comprised of cartilage producing
chondrocytes embedded in a proteoglycan-rich extra cellular matrix.
We noted signiﬁcant modiﬁcations of the epiphysis in CBZ treated ani-
mals and therefore quantiﬁed the area of resting/proliferating and hy-
pertrophic chondrocytes (in mm2), respectively (Fig. 4A) after a 5-
and 8-dose regimen of CBZ or CTRL. Additionally we analysed tumour-
free tibiae collected in previously published tumour models [5,32], in
order to assess effects of longer-term CBZ treatment.
Five daily administrations of CBZ resulted in a signiﬁcant increase in
the hypertrophic chondrocyte zone in both, 8–9- (p ≤ 0.0001, Fig. 4B,
Table 2) and 17-week old female GFP Ob+ mice (p ≤ 0.001, Fig. 4C,
Table 2) Similarly, a 10-day course (8 administrations) of CBZ increased
the hypertrophic chondrocyte area in all the animal models when com-
pared to control (6-week old male BALB/c nude: p ≤ 0.001, Fig. 4D; 9-
week old GFP Ob+: p ≤ 0.01, Fig. 4E; 6-week old female BALB/c nude:
p ≤ 0.0001, Fig. 4F; Table 2). Next to the elongated hypertrophic zones,
the chondrocyte stacks appeared disorganized in CBZ treated animals
compared to control (Fig. 4B,D&E). The CBZ-induced increase in growth
plate thicknesswas reversed to control levelswithin 5 days of treatment
termination (Fig. 4 F, Table 2). In addition to the increased hypertrophicchondrocyte area the area of resting/proliferating chondrocytes was
smaller in animals receiving 5 (8–9-week old GFP Ob+: p ≤ 0.05,
Fig. 4B; 17-week old female GFP Ob+: p ≤ 0.05, Fig. 4C; Table 2) and
10 doses of CBZ (9-week old GFP Ob+: p ≤ 0.001, Fig. 4E, Table 2; 6-
week old female BALB/c nude: p ≤ 0.0001, Fig. 4F; Table 2). Treatment
follow-up analysis in 6-week old female BALB/c nude mice revealed
that also the resting/proliferating chondrocyte area reached control
levels as quickly as 5 days post CBZ treatment termination (Fig. 4F,
Table 2). These results demonstrate that CBZ induces reversible alter-
ations to the epiphyseal growth plate by disrupting chondrocyte differ-
entiation. Material from previously published studies allowed us to
determine the effects on the growth plate on histological samples
from contralateral, tumour free tibiae following longer-term treatment
with CBZ, Table 2 [5,32]. In agreement with our short-term studies, cas-
tratedmale NOD/SCIDmice that had received daily administration of 30
mg/kg CBZ for 15 days had a signiﬁcantly elongated hypertrophic chon-
drocyte area when compared to control mice (p ≤ 0.001, Fig. 4G,
Table 2). Similar results were observed after 6-week treatment with
60 mg/kg CBZ (p ≤ 0.01, Fig. 4H) of castrated male beige SCID mice
and no alteration in the proliferative/resting chondrocyte zone was de-
termined in either of these experiments (Fig. 4G&H, Table 2).
3.4. Effects of Cabozantinib on bone marrow composition
During our analyseswe observed that CBZ caused alterations in bone
marrow composition. In particular, CBZ-treated animals appeared to
have increased numbers of red blood cells in the bonemarrow associat-
ed with numerous megakaryocytes. We therefore determined the
Fig. 4. Effects of Cabozantinib on the epiphyseal growth plate. (A) Schematic illustration of growth plate quantiﬁcation after administration of 30 mg/kg Cabozantinib (CBZ) or sterile H2O
control (CTRL). Itwas interactively drawn around the hypertrophic (Hyp) and resting/proliferating (Res/Prol) chondrocyte zone of the epiphysis using OsteoMeasure software. Effects of 5
doses (n=4/group) of CBZ or CTRL on the epiphyseal growthplate are shown in (B) for 8–9- and (C) 17-week old female GFPOb+mice. Alterations in growth plate composition following
8 doses of CBZ or CTRL are presented in (D) 6-week old male BALB/c nude (n= 4/group), (E) 9-week old GFP Ob+ (n= 4/group) and (F) 6-week old female BALB/c nude mice (day 10:
n=4CBZ; n=5/group/time point). Representative Safranin-O stained histological sections of tibiae are shown in (B,D&E). Effects on the growth plate after 30mg/kg CBZ or CTRL daily for
15 days in NOD/SCIDmice (n= 6 CTRL, n = 7 CBZ), are presented in (D). (E) highlights effects after 60 mg/kg CBZ or CTRL 5× weekly for 6 weeks in 6-week old of castrated male beige
SCIDmice (n=9 CTRL, n=10 CBZ). 20× objective, scale bar is 50 μm. Student's t-test or (F) two-wayANOVAwith Bonferroni post-test, * is p ≤ 0.05, ** is p ≤ 0.01, *** is p ≤ 0.001, **** is p ≤
0.0001. AOI is area of interest. All data show mean ± SEM.
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scoring H&E stained sections of tibiae as illustrated in Fig. 5A. In BALB/
c nude mice, 8 administrations of CBZ resulted in increased numbers
of megakaryocytes/mm2 tissue area when compared to control (Male
BALB/c nude: CTRL: 42.50 ± 3.09 vs. CBZ: 58.52 ± 0.88, p ≤ 0.01,
Fig. 5B; Female BALB/c nude: CTRL: 38.91 ± 2.37 vs. CBZ: 47.30 ±
1.77, p ≤ 0.05, Fig. 5B&D). Megakaryocyte numbers reduced 5 days
after the last administration of CBZ (CTRL: 37.76 ± 1.95 vs. CBZ:
27.43 ± 2.30, Fig. 5C) and normalised to control levels by day 12
(CTRL: 39.25 ± 5.66 vs. CBZ: 37.44 ± 1.24, Fig. 5C).
In addition to the changes to the bone microenvironment described
above, histological analysis revealed that overall bone marrow cellular-
ity was notably reduced in CBZ treated animals compared to control.
Administration of 8 doses of CBZ resulted in vascular ectasia and spillage
of mature (non-nucleated) red blood cells amongst the extra vascular
bone marrow cells (Fig. 5D). Haemangioma-like bone marrow blood
vessels, whichwere densely ﬁlled with erythrocytes, were observed, lo-
cally replacing the normal haematopoietic bone marrow (Fig. 5C,
Fig. 6D–F). The dilated vessels appeared thin walled compared to the
ones observed in control bonemarrow although this requires conﬁrma-
tion (Fig. 6A–F). The effects were most prominent after 8 administra-
tions of CBZ, with similar but less prominent alterations observed after
5 doses. Alterations in bonemarrow vasculature and spillage of erythro-
cytes were rapidly lost once CBZ treatment was terminated, with nor-
mal bone marrow restored by day 15 (Fig. 5C&D).Taken together, these data show that CBZ affects the bone microen-
vironment through modiﬁcation of multiple cell types, including bone
cells and cells of the haematopoietic marrow.
4. Discussion
Improving outcome for patients with skeletal metastases requires
effective therapeutic targeting of both tumour cells and the supporting
bonemicroenvironment, ideally using a single agent that modiﬁesmul-
tiple targets involved in driving both tumour growth and cancer-
induced bone disease. The small molecule tyrosine kinase (RTK) inhib-
itor Cabozantinib (CBZ) is an agent that ﬁts this proﬁle, as it inhibits
multiple RTKs that have important roles in tumour growth as well as
in bone biology. CBZ has shown activity in clinical trials in prostate can-
cer, improving progression free survival, reducing pain and resulting in
partial and or complete resolution in bone scans [7]. The authors of the
study highlighted that CBZmay not only exert effects on the tumour di-
rectly, but also indirectly through targeting cells of the bonemicroenvi-
ronment. However, it remains to be established whether these effects
are tumour-independent. To date, the majority of experiments investi-
gating CBZ effects on tumour growth in bone have been performed in
models of advanced prostate cancer [5,32,33], where substantial bone
loss and large tumour burden has hampered analysis of CBZ responses
on bone. Here we present the ﬁrst detailed characterisation of the ef-
fects of CBZ on tumour-free bone in vivo, providing evidence that the
Table 2
Treatment effects of Cabozantinib (CBZ) on the hypertrophic and resting/proliferating
chondrocyte zone of the epiphyseal growth plate area (in mm2) were analysed after 5
and 8 dose regimen of 30 mg/kg CBZ or control (CTRL) on histological sections of tibiae
using OsteoMeasure software and normalised to total growth plate area. Student's t-test
was used for statistical analysis or (1)two-way ANOVA with Bonferroni post-test. ns is
non-signiﬁcant, * is p ≤ 0.05, ** is p ≤ 0.01, *** is p ≤ 0.001, **** is p ≤ 0.0001.
Hypertrophic chondrocyte zone area (mm2)
CTRL CBZ p
5 doses of CBZ
8–9-week old GFP Ob+ mice 0.305 ± 0.015 0.537 ± 0.017 ****
17-week old GFP Ob+ mice 0.171 ± 0.010 0.403 ± 0.025 ***
8 doses of CBZ
6-week old male BALB/c nude 0.276 ± 0.004 0.549 ± 0.041 ***
6 week old female BALB/c nude 0.278 ± 0.016 0.514 ± 0.035 **** (1)
8–9-week old female GFP Ob+ 0.275 ± 0.018 0.409 ± 0.028 **
Treatment follow-up
5 days post-treatment termination 0.292 ± 0.022 0.319 ± 0.005 ns (1)
12 days post-treatment termination 0.335 ± 0.020 0.282 ± 0.019 ns (1)
Longer term treatment
Castrated male NOD/SCID mice 0.232 ± 0.024 0.481 ± 0.034 ***
Castrated male beige SCID mice 0.203 ± 0.023 0.372 ± 0.047 **
5 doses of CBZ
8–9-week old GFP Ob+ 0.297 ± 0.019 0.226 ± 0.012 *
17-week old GFP Ob+ 0.254 ± 0.016 0.207 ± 0.009 *
8 doses of CBZ
6-week old male BALB/c nude 0.269 ± 0.048 0.211 ± 0.018 ns
6 week old female BALB/c nude 0.406 ± 0.021 0.285 ± 0.017 **** (1)
8–9-week old female GFP Ob+ 0.337 ± 0.014 0.212 ± 0.006 ***
Treatment follow-up (6-week old female BALB/c nude)
5 days post-treatment termination 0.387 ± 0.008 0.381 ± 0.016 ns (1)
12 days post-treatment termination 0.414 ± 0.011 0.392 ± 0.014 ns (1)
Longer term treatment
Castrated male NOD/SCID mice 0.238 ± 0.021 0.205 ± 0.013 ns
Castrated male beige SCID mice 0.174 ± 0.013 0.200 ± 0.019 ns
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microenvironment. Breast cancer preferentially metastasises to bone
hence indicating thepotential of CBZ as a potential treatment.We there-
fore included female animal models in our experiments.
Osteoblasts and osteoclasts are key players in the vicious cycle driv-
ing progression of bonemetastasis [36], and crucially both cell types ex-
press receptors targeted by CBZ [2–4]. In agreement with this, CBZ
modiﬁes proliferation and differentiation of both osteoclasts and osteo-
blasts in vitro. A recent study reported inhibition of differentiation and
resorptive activity in RAWpre-osteoclast cells in addition to reduced vi-
ability and osteocalcin levels (a marker for late osteoblast differentia-
tion) in pre-osteoblastic MC3T3-E1 and mouse bone marrow stromal
ST-2 cell cultures following CBZ treatment (0.01–5 μmol/L) [33]. CBZ al-
tered alkaline phosphatase activity (amarker for early osteoblast differ-
entiation) in a biphasic fashion but did not modify mineralisation [33].
In contrast, Nguyen et al. found an increase in mineralisation, reduced
proliferation and stimulated alkaline phosphatase activity in MC3T3
cells as a consequence of CBZ treatment (0.01–3 μmol) [32]. Stern and
colleagues also reported that treatment of osteoblastic MC3T3-E1 cells
with 3 μM CBZ for 24 h reduced the expression of RANKL and alkaline
phosphatase and inhibited proliferation in a dose dependent fashion
after 48 h [37]. A 3 μM dose of CBZ did not alter expression of TRAP
and cathepsin K in RAW 264.7 pre-osteoclastic cells. However, co-
treatmentwith 2–3 μMCBZ and 20 ng/mLRANKL for 5 days (to promote
osteoclastogenesis) inhibited the expected RANKL-induced increase in
TRAP activity and cell proliferation [37]. The authors concluded that
CBZ may act on bone through more than one mechanism, based on
the biphasic effects caused by different concentrations of CBZ. In addi-
tion, Schimmoller and colleagues have reported a dose-dependent de-
crease of osteoclast differentiation by CBZ in vitro that did not impedethe ability of mature osteoclasts to resorb bone. They also found a bi-
phasic effect of CBZ, with increased osteoblast differentiation and bone
forming activity at the lower doses but a reduction at higher doses
[38]. In vivo the tight coupling between osteoblasts and osteoclasts
makes it difﬁcult to separate the direct/indirect effects of therapeutic
agents on these cells, in particular when both cell types express the tar-
get receptor(s). It is possible that CBZ reduced RANKL expression by the
osteoblasts in our study, resulting in decreased osteoclast number.
However it is not possible to accurately measure the levels of active
RANKL in the bone microenvironment and the role of soluble RANKL
in regulating bone turnover is unclear. Although we were unable to de-
tect a CBZ-mediated reduction in osteoclast (serumTRAP) activity at the
end of the study, the highly signiﬁcant increase in the length of the hy-
pertrophic chondrocyte zone provides strong evidence that resorption
is impaired.
The in vivo effects of CBZ on osteoblasts and osteoclasts in the ab-
sence of tumour cells have not been investigated in detail. We therefore
used a variety of in vivomodels, includingmice of different ages, sex and
strain, to perform the ﬁrst comprehensive analysis of the effects of CBZ
on osteoblast and osteoclast number in a range of bone microenviron-
ments. Here we report that CBZ is able to modify bone cells in the ab-
sence of tumour. Performing experiments across a spectrum of animal
models (young/old, female/male) enabled us to determine the degree
of variability between these. Interestingly, we observed inconsistency
in the effects CBZ on osteoblasts and osteoclasts depending on the age
of the animal model. This demonstrates that the level of bone turnover
(decreasing with age) may be important in determining the effects of
this agent on bone. Overall, CBZ rapidly reduced the number of osteo-
clasts/mm trabecular bone surface resulting in increased trabecular
thickness after a cumulative dose of 240mg/kg (8 administrations). Os-
teoblast numbers/mm trabecular bone was signiﬁcantly increased after
5 doses of CBZ (150 mg/kg cumulative dose) however no effects on os-
teoblasts were observed after 8 administrations in female animals
(Fig. 3C&E). Male BALB/c nude mice showed a slight increase in osteo-
blast numbers. It remains unclear whywe observe differences in osteo-
blast and osteoclast number in mice of different sex, however we found
that CBZ-induced alterations of megakaryocyte number, bone marrow
vasculature, trabecular thickness and elongated hypertrophic chondro-
cyte zone in the epiphyseal growth plate area were all consistently ob-
served in both male and female mice. Our experiments therefore
highlight the need to perform studies in different animal ages/sex in
order to demonstrate consistency of therapeutic effects in model
systems.
Only limited data are available from tumourmodels evaluating CBZ-
induced effects on bone cells and to our knowledge the majority have
been performed in tumour-bearing models. In a study of prostate
cancer-induced bone disease, male NOD/SCID mice receiving 30
mg/kg CBZ for 15 days had signiﬁcantly reduced numbers of osteo-
clasts/mm trabecular bone surface along the edge of the growth plate
of non-tumour bearing tibiae [5]. Nude mice injected intratibially with
the prostate cancer cell line ARCaPM receiving 10 or 30 mg/kg CBZ
daily for 7 weeks showed increased numbers of osteoblasts but no
change in osteoclast numbers in trabecular bone when compared to
control [38]. In addition, Dai and colleagues report increased osteoblast
perimeter and decreased osteoclast perimeter in non-tumour bearing
tibiae of male SCID mice with intratibial PC-3luc prostate tumours, fol-
lowing daily administration of 60 mg/kg CBZ for 3 weeks [33]. Serum
PINP and osteocalcin levels were unaffected by CBZ but TRAP5b levels
increased. The authors therefore suggest that CBZ might not affect the
resorptive activity of osteoclasts but rather inhibit osteoclastmaturation
[33].
The bone serummarker levels (TRAP and PINP) did not correspond
with the observed alterations in bone cell number (Supplementary
Fig. S1), due to the design of our experiments. Serum samples for
bonemarkermeasurementswere only collected at the endof the exper-
iment (reﬂecting one point in time). In contrast, histological analysis
Fig. 5. Effects of Cabozantinib on bonemarrow cellularity. (A)Megakaryocytes/mm2 tissue area were scored 125 μmaway from the growth plate as illustrated. An areawith a total length
of 1250 μmwas scored. (B) Number of megakaryocytes was scored after 8 administrations of 30 mg/kg CBZ or sterile H2O control for 10 days using 6-week old male (n = 4/group) and
female (n = 4-5/group) BALB/c nude mice. (C) Megakaryocyte number 5 (day 15) and 12 days (day 22) after the last CBZ administration in 6-week old female BALB/c nude mice. Rep-
resentative H&E stained tissue sections illustrating effects onmegakaryocytes and bonemarrow cellularity are demonstrated in (D), 20× objective, scale bar is 50 μm. Black asterisk points
out megakaryocytes. (B) Student's t-test, * is p ≤ 0.05, ** is p ≤ 0.01. (C) Two-way ANOVA with Bonferroni post-test. All data show mean ± SEM.
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od. Additionally, serum TRAP/PINP levels represent levels released from
the entire skeleton whereas we only quantiﬁed bone cell number in
tibia, potentially contributing to the observed differences.
Although 5 administrations of CBZ increased osteoblast and de-
creased osteoclast numbers, this short-term schedule did not result in
any signiﬁcant increase in trabecular bone volume, apart from in 17-
week old female GFP Ob+ mice (Fig. 2). Increasing the schedule to 8
doses of CBZ over 10 days did result in increased trabecular thickness
in all themodels evaluated in addition to increased trabecular bone vol-
ume and number in 9-week old female GFP Ob+mice (Table 1). This in-
crease was rapidly lost, returning to control levels 5 days after the last
administration of CBZ (Table 1). Although the GFP Ob+ mice represent
a slightly different bone microenvironment compared to BALB/c nude
mice, the differential effects of CBZ on trabecular bone is most likely
due to the difference in bone turnover between the mice aged 6 and 9
weeks. Our ﬁndings highlight that long-term and continuous treatment
might be required for bone volume to be altered, but following cessation
of treatment the bonemicroenvironment has the capacity to reverse the
alterations. In contrast to our results, Dai and colleagues found no in-
crease in bone mineral content in tumour free murine tibiae receiving
60 mg/kg CBZ for 3 weeks (PC3 tumours) and 5 weeks (Ace1 and C4-
2B tumours), respectively. The authors suggested that it may take lon-
ger to see treatment effects on bone than the 7-week treatment course
[33]. However, 6-week treatment with 60 mg/kg CBZ in castrated and
intact mice injected with LuCaP 23.1 prostate cancer cells resulted in
signiﬁcantly increased trabecular bone volume and number incontralateral non-tumour bearing tibiae [32]. These differences may
be due to themodels and CBZ schedules used, and further studies are re-
quired to ﬁrmly establish the optimal CBZ dosing regimen required to
increase bone volume.
We found substantial alterations in the epiphyseal growth plate of
CBZ treated mice, including expansion of the hypertrophic chondrocyte
zone. This was prominent in the epiphysis of all animals irrespective of
age, sex and treatment schedule. When we analysed growth plates of
tumour-free tibiae from animals receiving longer-term CBZ treatment
[5,32] similar effects were observed (Fig. 4). During endochondral ossi-
ﬁcation, newly synthesized cartilage is replaced by woven bone in a
highly organised process involving chondrocyte proliferation, matura-
tion, hypertrophy and ﬁnally matrix calciﬁcation. There are conﬂicting
views about the terminal fate of the chondrocyte, including their differ-
entiation into osteoblastic cells [39] or apoptosis (reviewed in [40]). It
has previously been reported that inhibition of VEGF signalling results
in growth plate thickening as a consequence of the expanded hypertro-
phic chondrocyte zone [4,41] and this could also be the mechanism in-
volved in the CBZ-induced effects. The growth plate normalised to
control thickness 12 days after treatment termination, coinciding with
an increase in osteoclast activity (Supplementary Fig. S2). During endo-
chondral ossiﬁcation, osteoclasts are recruited to the mineralizing front
of the growth plate, allowing resorption of cartilage and invasion of os-
teoblasts to mineralise the matrix, which is a potential explanation for
the sudden increase in osteoclast activity once CBZ administration
ceased. New blood vessel formation is apparent in the developing
epiphysis and anti-VEGF treatment has been shown to modify the
Fig. 6. Effects of Cabozantinib on the bonemarrow vasculature. Bonemarrow vasculature was visualized using immunoﬂuorescence staining against endomucin. Representative histolog-
ical sections of tibiae from 6-week old male BALB/c nude mice receiving 8 doses 30 mg/kg CBZ (D–F) or sterile H2O control (A–C) are shown. Representative images showing vascular
composition in the epiphyseal area of the tibia are shown in (A) for control and (D) for CBZ treatedmice. 20× objective, scale bar is 50 μm. CBZ induced effects on bonemarrow vascularity
(shown in B,C,E &F), 40× objective and scale bar is 50–100 μm, respectively. GP = growth plate, white arrowheads point out a subset of vessels.
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monitoring when receiving anti-angiogenic therapy as they are in risk
of developing growth plate abnormalities [42]. Our results suggest
that this approach is appropriate also for CBZ, although preliminary
safety data from a phase 1 trial of CBZ in paediatric cancer patients did
not indicate clinical consequences of potential growth plate effects [43].
We also noted alterations in bonemarrow composition in CBZ treat-
ed animals compared to control, including vascular ectasia and spillage
of mature red blood cells in the extra vascular bonemarrow (Fig. 6). Di-
lated blood vessels densely ﬁlled with erythrocytes were observed in
the bone marrow of mice that had received 8 administrations of CBZ
(Fig. 6).Mice that received 15days of treatment [5] appeared to have re-
duced haematopoietic cells in themarrow, increased numbers of adipo-
cytes and reducedmegakaryocyte cytoplasm, although wewere unable
to accurately quantify this due to the limited number of samples avail-
able from this study. Analysis of histological sections from tibiae of
mice receiving 60 mg/kg CBZ 5× weekly for 6 weeks [32] showed sim-
ilar changes in bone marrow composition in 3 out of 8 assessed mice,
with additional animals displaying a more modest effect. These re-
sponses are likely a result of inhibition of VEGFR affecting the bone mi-
crovasculature. In support of this, a study using the soluble VEGF
receptor chimeric protein Flt(1–3)-IgG reported an increase in thick-
ness of secondary trabeculi in vivo. In addition, animals displayed disor-
ganized and dilated blood vessels adjacent to the hypertrophic
chondrocyte zone [4] with similar morphology as observed in our stud-
ies (Fig. 7A&D).
Next to fatigue, hypertension and hand–foot syndrome were the
most common experienced grade 3 adverse events caused by CBZ in pa-
tients with advanced prostate cancer [7]; lymphopenia, neutropenia
and thrombocytopenia in addition to haemorrhage have been reportedas common haematological adverse effects [44]. The bone marrow ef-
fects we observed in our experiments may therefore reﬂect some of
the known complications experienced by patients treated with CBZ.
One of ourmost intriguing ﬁndingswas that CBZ treatment caused a
signiﬁcant increase in the number of megakaryocytes in the bone mar-
row (Fig. 5), indicating that CBZmay have impaired terminal differenti-
ation of megakaryocytes and release of platelets. The increase in red
blood cells in the marrow could be in agreement with thrombocytope-
nia reported as a common laboratory abnormality in patients receiving
CBZ [44]. However, as with all the CBZ-induced effects detected in our
study, megakaryocyte numbers and the associated bonemarrow effects
rapidly normalised to control levels once treatment was terminated
(Fig. 6). Megakaryocytes also play a role in bone homeostasis, including
in the maintenance of bone mass [45]. Mice deﬁcient in the transcrip-
tion factors required for megakaryocyte differentiation and maturation
have high numbers of immature megakaryocytes in the bone marrow,
accompanied by dramatically increased osteoblast numbers and bone
volume [26]. In vitro, osteoblast proliferation is increased by the pres-
ence of megakaryocytes and direct cell-to cell contact between both
cell types is suggested to occur via gap junctions [46] and/or integrins
[47]. However, towhat extent osteoblasts andmegakaryocytes are in di-
rect contact in vivo remains to be established. In the present study,
megakaryocytes did not appear to be in close proximity to osteoblasts
in histological sections of tibiae (Fig. 5). Megakaryocytes have also
been demonstrated to inhibit formation of osteoclasts when added to
pre-osteoclast cultures and to impair osteoclast function [28,48]. It is
therefore possible that CBZmay increase bone volume not only through
direct effects on osteoblasts and osteoclasts, but also indirectly through
increasing the number of megakaryocytes that in turn stimulate osteo-
blasts and inhibit osteoclast activity and maturation.
591M.-T. Haider et al. / Bone 81 (2015) 581–5925. Conclusion
Collectively our data suggest that CBZ exerts effects on different cell
types in the bone microenvironment including cells of the bone mar-
row. Response of key bone cells to CBZ administration are rapid and re-
versible once treatment is stopped, supporting the conclusion that
continuous administration is required in order to maintain the effects
of this agent.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2015.08.003.
Author contributions
MTH performed experiments, participated in study design, carried
out analysis of data, data presentation and participated in drafting and
revising themanuscript IH participated in study design, data interpreta-
tion, critical evaluation, revision and drafting of the manuscript. NJ
Brown participated in drafting and revising themanuscript and critical-
ly reviewed its content in addition to holding the PPL for the in vivo
studies and providing advice on in vivo protocols and individual study
plans. KH assessed histological sections, assisted with data interpreta-
tion and manuscript revision. TND generated the pOBCol2.3GFPemd
mice. RH participated in experimental optimisation and manuscript re-
vision. SP Robinson, TJ Grahamand E Corey provided samples from their
related experimental work and reviewed the manuscript. All authors
take responsibility for their work, have read and given ﬁnal approval
for publication of this manuscript.
Conﬂict of interest
This studywas partially funded by a research grant from Exelixis Inc.
Source of funding
This research was supported by Exelixis, Inc. (R/136892), Breast
Cancer Campaign (UK) (2010NovPhD17) and CR-UK Imaging Centre
grant (C1060/A10334).
Competing interests
The authors declare that there are no competing interests.
Acknowledgements
We thank M Kinch and CA Evans for expert technical support, HK
Brown for guidance on protocol optimization and D Robinson for assis-
tance with confocal microscopy. We also thank S Sutherland and R
Rodham for assistance in laboratory and in vivo experiments,
respectively.
References
[1] F.M. Yakes, J. Chen, J. Tan, K. Yamaguchi, Y. Shi, P. Yu, F. Qian, F. Chu, F. Bentzien, B.
Cancilla, et al., Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simulta-
neously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer Ther.
10 (12) (2011) 2298–2308.
[2] M. Grano, F. Galimi, G. Zambonin, S. Colucci, E. Cottone, A.Z. Zallone, P.M. Comoglio,
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro,
Proc. Natl. Acad. Sci. U. S. A. 93 (15) (1996) 7644–7648.
[3] M.M. Deckers, M. Karperien, C. van der Bent, T. Yamashita, S.E. Papapoulos, C.W.
Löwik, Expression of vascular endothelial growth factors and their receptors during
osteoblast differentiation, Endocrinology 141 (5) (2000) 1667–1674.
[4] H.P. Gerber, T.H. Vu, A.M. Ryan, J. Kowalski, Z.Werb, N. Ferrara, VEGF couples hyper-
trophic cartilage remodeling, ossiﬁcation and angiogenesis during endochondral
bone formation, Nat. Med. 5 (6) (1999) 623–628.
[5] T.J. Graham, G. Box, N. Tunariu, M. Crespo, T.J. Spinks, S. Miranda, G. Attard, J. de
Bono, S.A. Eccles, F.E. Davies, et al., Preclinical evaluation of imaging biomarkers
for prostate cancer bone metastasis and response to cabozantinib, J. Natl. Cancer
Inst. 106 (4) (2014).[6] H.M. Nguyen, N. Ruppender, X. Zhang, L.G. Brown, T.S. Gross, C. Morrissey, R. Gulati,
R.L. Vessella, F. Schimmoller, D.T. Aftab, et al., Cabozantinib inhibits growth of
androgen-sensitive and castration-resistant prostate cancer and affects bone re-
modeling, PLoS ONE 8 (10) (2013), e78881.
[7] D.C. Smith, M.R. Smith, C. Sweeney, A.A. Elﬁky, C. Logothetis, P.G. Corn, N.J.
Vogelzang, E.J. Small, A.L. Harzstark, M.S. Gordon, et al., Cabozantinib in patients
with advanced prostate cancer: results of a phase II randomized discontinuation
trial, J. Clin. Oncol. 31 (4) (2013) 412–419.
[8] M.R. Smith, C.J. Sweeney, P.G. Corn, D.E. Rathkopf, D.C. Smith, M. Hussain, D.J.
George, C.S. Higano, A.L. Harzstark, A.O. Sartor, et al., Cabozantinib in
chemotherapy-pretreated metastatic castration-resistant prostate cancer: results
of a phase II nonrandomized expansion study, J. Clin. Oncol. 32 (30) (2014)
3391–3399.
[9] E. Basch, K.A. Autio, M.R. Smith, A.V. Bennett, A.L. Weitzman, C. Scheffold, C.
Sweeney, D.E. Rathkopf, D.C. Smith, D.J. George, et al., Effects of cabozantinib on
pain and narcotic use in patients with castration-resistant prostate cancer: results
from a phase 2 nonrandomized expansion cohort, Eur. Urol. 67 (2) (2015) 310–318.
[10] D.L. Lacey, E. Timms, H.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, R. Elliott, A.
Colombero, G. Elliott, S. Scully, et al., Osteoprotegerin ligand is a cytokine that regu-
lates osteoclast differentiation and activation, Cell 93 (2) (1998) 165–176.
[11] J. Tombran-Tink, C.J. Barnstable, Osteoblasts and osteoclasts express PEDF, VEGF-A
isoforms, and VEGF receptors: possible mediators of angiogenesis and matrix re-
modeling in the bone, Biochem. Biophys. Res. Commun. 316 (2) (2004) 573–579.
[12] H. Otomo, A. Sakai, S. Uchida, S. Tanaka, M. Watanuki, S. Moriwaki, S. Niida, T.
Nakamura, Flt-1 tyrosine kinase-deﬁcient homozygousmice result in decreased tra-
becular bone volume with reduced osteogenic potential, Bone 40 (6) (2007)
1494–1501.
[13] V. Gattei, D. Aldinucci, J.M. Quinn, M. Degan, M. Cozzi, V. Perin, A.D. Iuliis, S. Juzbasic,
S. Improta, N.A. Athanasou, et al., Human osteoclasts and preosteoclast cells (FLG
29.1) express functional c-kit receptors and interact with osteoblast and stromal
cells via membrane-bound stem cell factor, Cell Growth Differ. 7 (6) (1996)
753–763.
[14] Y.Q. Yang, Y.Y. Tan, R. Wong, A. Wenden, L.K. Zhang, A.B. Rabie, The role of vascular
endothelial growth factor in ossiﬁcation, Int. J. Oral. Sci. 4 (2) (2012) 64–68.
[15] R.J. Lee, M.R. Smith, Targeting MET and VEGFR signaling in castration-resistant pros-
tate cancer, Cancer J. (Sudbury, Mass) 19 (1) (2013) 90–98.
[16] R.S. Taichman, Blood and bone: two tissues whose fates are intertwined to create
the hematopoietic stem-cell niche, Blood 105 (7) (2005) 2631–2639.
[17] K.M. Weidner, J. Behrens, J. Vandekerckhove, W. Birchmeier, Scatter factor: molecu-
lar characteristics and effect on the invasiveness of epithelial cells, J. Cell Biol. 111 (5
Pt 1) (1990) 2097–2108.
[18] V. Brinkmann, H. Foroutan, M. Sachs, K.M. Weidner, W. Birchmeier, Hepatocyte
growth factor/scatter factor induces a variety of tissue-speciﬁc morphogenic pro-
grams in epithelial cells, J. Cell Biol. 131 (6 Pt 1) (1995) 1573–1586.
[19] F. Bussolino, M.F. Di Renzo, M. Ziche, E. Bocchietto, M. Olivero, L. Naldini, G. Gaudino,
L. Tamagnone, A. Coffer, P.M. Comoglio, Hepatocyte growth factor is a potent angio-
genic factor which stimulates endothelial cell motility and growth, J. Cell Biol. 119
(3) (1992) 629–641.
[20] C. Birchmeier, W. Birchmeier, E. Gherardi, G.F. Vande Woude, Met, metastasis, mo-
tility and more, Nat. Rev. Mol. Cell Biol. 4 (12) (2003) 915–925.
[21] K.P. Raghav, W. Wang, S. Liu, M. Chavez-MacGregor, X. Meng, G.N. Hortobagyi, G.B.
Mills, F. Meric-Bernstam, G.R. Blumenschein, A.M. Gonzalez-Angulo, cMET and
phospho-cMET protein levels in breast cancers and survival outcomes, Clin. Cancer
Res. 18 (8) (2012) 2269–2277.
[22] S.Y. Tsai, Y.L. Huang, W.H. Yang, C.H. Tang, Hepatocyte growth factor-induced BMP-
2 expression is mediated by c-Met receptor, FAK, JNK, Runx2, and p300 pathways in
human osteoblasts, Int. Immunopharmacol. 13 (2) (2012) 156–162.
[23] R. Taichman, M. Reilly, R. Verma, K. Ehrenman, S. Emerson, Hepatocyte growth fac-
tor is secreted by osteoblasts and cooperatively permits the survival of
haematopoietic progenitors, Br. J. Haematol. 112 (2) (2001) 438–448.
[24] E. Sonnenberg, D. Meyer, K.M. Weidner, C. Birchmeier, Scatter factor/hepatocyte
growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal ex-
change between mesenchyme and epithelia during mouse development, J. Cell
Biol. 123 (1) (1993) 223–235.
[25] K. Takai, J. Hara, K. Matsumoto, G. Hosoi, Y. Osugi, A. Tawa, S. Okada, T. Nakamura,
Hepatocyte growth factor is constitutively produced by human bone marrow stro-
mal cells and indirectly promotes hematopoiesis, Blood 89 (5) (1997) 1560–1565.
[26] M.A. Kacena, R.A. Shivdasani, K. Wilson, Y. Xi, N. Troiano, A. Nazarian, C.M.
Gundberg, M.L. Bouxsein, J.A. Lorenzo, M.C. Horowitz, Megakaryocyte–osteoblast
interaction revealed in mice deﬁcient in transcription factors GATA-1 and NF-E2, J.
Bone Miner. Res. 19 (4) (2004) 652–660.
[27] I. Casella, T. Feccia, C. Chelucci, P. Samoggia, G. Castelli, R. Guerriero, I. Parolini, E.
Petrucci, E. Pelosi, O. Morsilli, et al., Autocrine–paracrine VEGF loops potentiate
the maturation of megakaryocytic precursors through Flt1 receptor, Blood 101 (4)
(2003) 1316–1323.
[28] C.A. Beeton, S. Bord, D. Ireland, J.E. Compston, Osteoclast formation and bone resorp-
tion are inhibited by megakaryocytes, Bone 39 (5) (2006) 985–990.
[29] D. Pfander, T. Cramer, G. Weseloh, O. Pullig, D. Schuppan, M. Bauer, B. Swoboda, He-
patocyte growth factor in human osteoarthritic cartilage, Osteoarthr. Cartil./OARS,
Osteoarthr. Res. Soc. 7 (6) (1999) 548–559.
[30] H.P. Gerber, T.H. Vu, A.M. Ryan, J. Kowalski, VEGF couples hypertrophic cartilage rem
odeling, ossiﬁcation and angiogenesis during endochondral bone formation, Nat.
Med. 5 (6) (1999) 623–628.
[31] R. Leonardi, R. Caltabiano, C. Loreto, The immunolocalization and possible role of c-
Met (MET, hepatic growth factor receptor) in the developing human fetal mandib-
ular condyle, Acta Histochem. 112 (5) (2010) 482–488.
592 M.-T. Haider et al. / Bone 81 (2015) 581–592[32] H.M. Nguyen, N. Ruppender, X. Zhang, Cabozantinib inhibits growth of androgen-
sensitive and castration-resistant prostate cancer and affects bone remodeling,
PLoS ONE 8 (10) (2013) 1–15.
[33] J. Dai, H. Zhang, A. Karatsinides, J.M. Keller, K.M. Kozloff, D.T. Aftab, F. Schimmoller,
E.T. Keller, Cabozantinib inhibits prostate cancer growth and prevents tumor-
induced bone lesions, Clin. Cancer Res. 20 (3) (2014) 617–630.
[34] M.-T. Haider, I. Holen, T.N. Dear, K. Hunter, H.K. Brown, Modifying the osteoblastic
niche with zoledronic acid in vivo—potential implications for breast cancer bone
metastasis, Bone 66 (2014) 240–250.
[35] H.K. Brown, P.D. Ottewell, C.A. Evans, I. Holen, Location matters: osteoblast and os-
teoclast distribution ismodiﬁed by the presence and proximity to breast cancer cells
in vivo, Clin. Exp. Metastasis 29 (8) (2012) 927–938.
[36] S.M. Käkönen, G.R. Mundy, Mechanisms of osteolytic bone metastases in breast car-
cinoma, Cancer 97 (3 Suppl.) (2003) 834–839.
[37] P.H. Stern, K. Alvares, Antitumor agent cabozantinib decreases RANKL expression in
osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone re-
sorption, J. Cell. Biochem. 115 (11) (2014) 2033–2038.
[38] F. Schimmoller, M. Zayzafoon, L.W.K. Chung, H.E. Zhau, K.M. Fagerlund, D.T. Aftab,
Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteo-
blastic and osteolytic progression of human prostate cancer xenografts in mouse
bone, Mol. Cancer Ther. 10 (11 Supplement) (2011) A233.
[39] X. Zhou, K. von der Mark, S. Henry, W. Norton, H. Adams, B. de Crombrugghe,
Chondrocytes transdifferentiate into osteoblasts in endochondral bone during de-
velopment, postnatal growth and fracture healing in mice, PLoS Genet. 10 (12)
(2014), e1004820.
[40] C.S. Adams, I.M. Shapiro, The fate of the terminally differentiated chondrocyte: evi-
dence for microenvironmental regulation of chondrocyte apoptosis, Crit. Rev. Oral
Biol. Med. 13 (6) (2002) 465–473.[41] S.R. Wedge, D.J. Ogilvie, M. Dukes, J. Kendrew, J.O. Curwen, L.F. Hennequin, A.P.
Thomas, E.S. Stokes, B. Curry, G.H. Richmond, et al., ZD4190: an orally active inhib-
itor of vascular endothelial growth factor signaling with broad-spectrum antitumor
efﬁcacy, Cancer Res. 60 (4) (2000) 970–975.
[42] S.D. Voss, J. Glade-Bender, S.L. Spunt, S.G. DuBois, B.C. Widemann, J.R. Park, S.E.
Leary, M.D. Nelson, P.C. Adamson, S.M. Blaney, et al., Growth plate abnormalities
in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report
from the Children's Oncology Group Phase I Consortium, Pediatr. Blood Cancer 62
(1) (2015) 45–51.
[43] M.K. Chuk, H.A.C. Widemann BC, J.M. Reid, A. Kim, J.J. Wright, M. Lodish, E. Fox, B.
Weigel, S. Blane, A phase I study of cabozantinib (XL184) in children and adoles-
cents with recurrent or refractory solid tumors, including CNS tumors: a Children's
Oncology Group phase I consortium trial, 2014 ASCO Annual Meeting, J Clin Oncol,
vol. 32, 2014 (5 s).
[44] R. Elisei, M.J. Schlumberger, S.P. Müller, P. Schöffski, M.S. Brose, M.H. Shah, L. Licitra,
B. Jarzab, V. Medvedev, M.C. Kreissl, et al., Cabozantinib in progressive medullary
thyroid cancer, J. Clin. Oncol. 31 (29) (2013) 3639–3646.
[45] M.A. Kacena, W.A. Ciovacco, Megakaryocyte–bone cell interactions, Adv. Exp. Med.
Biol. 658 (2010) 31–41.
[46] W.A. Ciovacco, C.G. Goldberg, A.F. Taylor, J.M. Lemieux, M.C. Horowitz, H.J. Donahue,
M.A. Kacena, The role of gap junctions inmegakaryocyte-mediated osteoblast prolif-
eration and differentiation, Bone 44 (1) (2009) 80–86.
[47] J.M. Lemieux, M.C. Horowitz, M.A. Kacena, Involvement of integrins
alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein IIb in megakaryocyte-
induced osteoblast proliferation, J. Cell. Biochem. 109 (5) (2010) 927–932.
[48] M.A. Kacena, T. Nelson, M.E. Clough, S.K. Lee, J.A. Lorenzo, C.M. Gundberg, M.C.
Horowitz, Megakaryocyte-mediated inhibition of osteoclast development, Bone 39
(5) (2006) 991–999.
